GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05785624
- Locations
- 🇲🇽
Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Southern Arizona VA Health Care System NAVREF PPDS, Tucson, Arizona, United States
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05673876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Massachusetts General Hospital; Harvard Medical School - Gi Unit Grj724, Boston, Massachusetts, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05660850
- Locations
- 🇦🇺
Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia
🇺🇸Southern California Institute For Respiratory, Los Angeles, California, United States
🇬🇧Queen Anne Street Medical Centre, London, United Kingdom
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05646836
- Locations
- 🇬🇷
University of Athens, Hematological Clinic,; First Department of Propaedeutic Medicine, Athens, Greece
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette)
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05626114
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retinal Consultants Medical Group, Sacramento, California, United States
🇺🇸West Coast Retina, San Francisco, California, United States
A Study to Characterize Access to Specialty Care Received by American Indians/Alaska Natives
- Conditions
- Interventions
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05624788
- Locations
- 🇺🇸
PPD Virtual - PPD - US, Wilmington, North Carolina, United States
🇺🇸Avera Research Institute, Sioux Falls, South Dakota, United States
🇺🇸Curebase, Walnut, California, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05581004
- Locations
- 🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇪🇸Hospital Universitario Virgen de la Victoria, Malaga, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05487235
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇵🇱Uniwersytecki Szpital Kliniczny w Poznaniu, Pozna?, Poland
🇪🇸NEXT Oncology-Hospital Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05462522
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Stanford University, Palo Alto, California, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- 🇺🇸
Alabama Oncology - Bruno Cancer Center, Birmingham, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸The Dignity Health Cancer Institute, Phoenix, Arizona, United States